ArticlePloS one2026
Alu hypomethylation in ischemic stroke: Associations with selected clinical characteristics.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated Alu methylation levels in 85 ischemic stroke patients and 50 healthy controls, using Alu-Combined Bisulfite Restriction Analysis (COBRA) a quantitative approach to assess methylation. Ischemic stroke patients had significantly lower overall Alu methylation as compared to controls (P < 0.0001). Alu methylation was negatively correlated with age in both the control group (r = -0.6131, P < 0.0001) and the ischemic stroke group (r = -0.2834, P = 0.0086). Moreover, among age-matched ischemic stroke patients, there remained a difference between control and ischemic stroke patients (P = 0.0182). Alu methylation remained associated with ischemic stroke status after adjustment for age and sex (adjusted OR = 0.841, 95% CI = 0.709-0.979, P = 0.0327). Within the ischemic stroke group, disease duration was not significantly correlated with Alu methylation in the unadjusted analysis (r = -0.1594, P = 0.1450). However, after adjustment for age and sex, longer disease duration was associated with lower Alu methylation (β = -0.556, 95% CI = -0.994 to -0.117, P = 0.0137). Alu methylation was lower in patients with a history of multiple stroke events (P = 0.0323) and in those with Fazekas scores of 2-3 (P = 0.0324) in the unadjusted comparisons, but neither association remained statistically significant after adjustment for age and sex (P = 0.0542 and P = 0.0684, respectively). Stroke circulation location was not associated with Alu methylation. These findings support an association between Alu methylation and ischemic stroke status. Longer disease duration was also associated with lower Alu methylation after adjustment for age and sex. However, the cross-sectional design does not establish causality, disease progression, or predictive or prognostic value. Longitudinal studies are needed to determine the clinical relevance of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.